Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Zavedos
| Field | Information |
|---|---|
| Medication Name | Zavedos |
| Generic Name | Idarubicin |
| Boxed/Label Warning | Myelosuppression, cardiotoxicity, secondary leukemia |
| Purpose | Treatment of acute myeloid leukemia (AML) |
| Mechanism of Action | Intercalates with DNA, inhibiting topoisomerase II, leading to DNA damage and cell death. |
| Dosage Forms | Intravenous injection |
| Available Strengths | 5 mg/5 mL, 10 mg/10 mL |
| Dosage Frequency | Typically administered intravenously once daily for 3 days in combination with other chemotherapy agents. |
| Common Side Effects | Nausea, vomiting, diarrhea, mucositis, alopecia, fever, infection, abdominal pain. |
| Serious Side Effects | Myelosuppression (decreased white blood cells, red blood cells, and platelets), cardiotoxicity (heart failure, arrhythmias), secondary leukemia, severe infections, liver damage. |
| Drug Interactions | Other chemotherapy drugs, hepatotoxic medications, cardiotoxic medications, vaccines. |
| Important Notes | Administered under the supervision of a qualified healthcare professional experienced in the use of cancer chemotherapeutic agents. Monitor blood counts and cardiac function during therapy. |
| Storage | Store refrigerated at 2° to 8°C (36° to 46°F). Protect from light. |
| Missed Dose | This medication is administered by a healthcare professional in a clinical setting, and a missed dose is unlikely. |
| Alternatives | Daunorubicin, Cytarabine, Fludarabine, Mitoxantrone. |
Zavedos Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Daunorubicin | DNA intercalation, topoisomerase II inhibition. | Another anthracycline used in AML treatment. |
| Cytarabine | Inhibits DNA polymerase. | Commonly used in combination with anthracyclines for AML treatment. |
| Fludarabine | Inhibits DNA synthesis. | Purine analog used in some AML regimens. |
| Mitoxantrone | DNA intercalation, topoisomerase II inhibition. | Synthetic anthracenedione with similar mechanisms to anthracyclines. |
Zavedos Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Nausea | Myelosuppression (anemia, thrombocytopenia, neutropenia) |
| Vomiting | Cardiotoxicity (heart failure, arrhythmias) |
| Diarrhea | Secondary leukemia |
| Mucositis (mouth sores) | Severe infections (pneumonia, sepsis) |
| Alopecia (hair loss) | Liver damage |
| Fever | Tumor Lysis Syndrome |
Zavedos Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) – Induction | 12 mg/m² | Not applicable (induction therapy) | Administered intravenously once daily for 3 days in combination with Cytarabine. |
| Acute Myeloid Leukemia (AML) – Consolidation | 12 mg/m² | Varies based on treatment protocol | Administered intravenously according to consolidation treatment plan. |
Zavedos Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $20 – $100 |
| Without Insurance (U.S.) | $150 – $250 |
| From Canada | $110 |
